|drug4017||pre_lunch Yoga-based breathing support Wiki||1.00|
|drug3943||morning Yoga-based breathing support Wiki||1.00|
|drug4016||pre_dinner Yoga-based breathing support Wiki||1.00|
|D011618||Psychotic Disorders NIH||0.71|
|D001523||Mental Disorders NIH||0.22|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Since the description of the first cases of infection in December 2019 in the Hubei province in China, a new coronavirus, called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged and caused a pandemic. This new virus is responsible for an infectious disease with respiratory and potent severe symptoms, called COVID-19 (coronavirus disease 2019). The first data concerned essentially the adult population and gave a clinical description of the disease. However, data is missing in the pediatric population. The first published studies indicate that children seem to have a lower risk to get a severe form of COVID-19. Except the case of a child with leukemia recently described with the diagnosis of COVID-19, there is currently no data about pediatric patients with an oncology history or under chemotherapeutic drugs. Cancers are rare among children and is estimated to concern about 1700 new cases in a year in France. Malignant tumor or its treatment can affect self-immunity, which could favor SARS-CoV-2 infection or its aggravation. Thus, the investigators propose in this study to collect data about French children with a cancer and diagnosed with COVID-19.The analysis of the collected data will refine clinical characteristics of SARS-CoV-2 infection in this population. It will be critical for elaborating recommendations for the management of COVID-19 in children with cancer.
Description: Type of cancer and/or underlying pathologies, oncologic treatments administrated before COVID-19 diagnosis.Measure: Oncologic data Time: through study completion, an average of 1 year
Description: Date of COVID-19 diagnosis, method of diagnosis (PCR and/or clinical signs and/or serology)Measure: COVID-19 diagnosis Time: through study completion, an average of 1 year
Description: Description of clinical signs at initial phase, days 7-10, days 15-20 and days 25-30Measure: Clinical signs Time: through study completion, an average of 1 year
Description: Description of biological signs at initial phase, days 7-10, days 15-20 and days 25-30Measure: Biological signs Time: through study completion, an average of 1 year
Description: chest X-rays and/or CT-scan description if performedMeasure: Radiological signs Time: through study completion, an average of 1 year
Description: Management in hospital or at home, use of specific drugs against SARS-CoV2, oxygen required or not, other drugs administrated to manage infection complications.Measure: COVID-19 management Time: through study completion, an average of 1 year
Description: type of sequelae if anyMeasure: Potent COVID-19 sequelae Time: through study completion, an average of 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports